21.11.2024 12:44:28
|
Zymeworks To Receive Milestone Payment From Jazz In Relation To FDA Approval Of Ziihera
(RTTNews) - Zymeworks (ZYME) announced, with Jazz Pharmaceuticals, that the FDA has granted accelerated approval of Ziihera 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer. Ziihera, or zanidatamab-hrii, was approved under accelerated approval.
In late 2022, Zymeworks entered into a license and collaboration agreement with Jazz Pharmaceuticals Ireland for the exclusive development and commercialization rights to zanidatamab across all indications in the United States, Europe, Japan and all other territories except for those Asia Pacific territories previously licensed by Zymeworks. Under the terms of the Jazz license and collaboration agreement, Zymeworks has earned a milestone payment of $25 million based on the FDA approval in BTC. Zymeworks is also eligible to receive up to a further $500 million in regulatory milestone payments and $862.5 million in commercial milestone payments, as well as tiered royalties of 10% to 20% of net sales by Jazz.
For More Such Health News, visit rttnews.com.
Analysen zu Zymeworks Inc Registered Shs
Jahresrückblick & Jahresausblick 2024/2025 – Wall Street Live mit Tim Schäfer
In unserem zweiwöchigen Format „Wall Street Live“ mit Tim Schäfer behandeln wir Topaktuelle Themen des Marktgeschehens.
👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Meistgelesene Nachrichten
Börse aktuell - Live Ticker
Vorweihnachtliche Zurückhaltung: SMI schlussendlich im Plus -- DAX geht schwächer aus dem HandelDer heimische Aktienmarkt schloss am Montag im Plus, wohingegen sich der deutsche Aktienmarkt abwärts bewegte.
finanzen.net News
Datum | Titel |
---|---|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |